Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025

Rhea-AI Summary

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has scheduled its Q2 2025 financial results release for August 5, 2025, after market close.

The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors can join via phone using the provided dial-in numbers and access code 7468193, or access the webcast through Ceribell's investor relations website.

News Market Reaction – CBLL

+1.48%

+1.48% Session move

In the trading session that priced this news, CBLL gained 1.48%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7468193. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com

Media Contact
Corrie Rose
Press@ceribell.com  

FAQ

When will Ceribell (CBLL) release its Q2 2025 earnings?

Ceribell will release its Q2 2025 financial results on August 5, 2025 after the market closes.

What time is Ceribell's Q2 2025 earnings conference call?

Ceribell's earnings conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025.

How can investors access Ceribell's Q2 2025 earnings call?

Investors can access the call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 7468193, or via webcast on Ceribell's investor relations website.

What does Ceribell (CBLL) company do?

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions.